CPZ Model Better Matches 79 MS Lesions, While LPC Captures Stronger Inflammatory Responses
Updated
Updated · Nature.com · May 18
CPZ Model Better Matches 79 MS Lesions, While LPC Captures Stronger Inflammatory Responses
4 articles · Updated · Nature.com · May 18
Single-cell analysis of 112,017 mouse cells and 321,565 human nuclei found cuprizone-induced demyelination more closely reproduced oligodendrocyte states seen in multiple sclerosis lesions than lysophosphatidylcholine.
CPZ uniquely triggered a stressed oligodendrocyte program marked by Cdkn1a and Nupr1, with broader overlap with human lesion genes—including loss of myelin-maintenance pathways—while both mouse models converged on an immune-responsive remyelination state expressing Socs3 and B2m.
LPC produced the stronger and longer-lasting innate immune reaction, with more proliferating microglia, perivascular macrophage enrichment and persistent damage-associated microglia during remyelination, making it a closer fit for inflammatory lesion environments.
Human MS tissue still showed greater heterogeneity than either mouse model, especially in oligodendrocyte progenitors and microglia across active, chronic and remyelinated lesions, indicating neither system fully captures disease complexity.
The authors say the results provide a cross-species atlas to guide model choice—favoring CPZ for oligodendrocyte stress and senescence-like dysfunction, and LPC for inflammatory dynamics and macrophage-related repair.
Scientists are refining mouse models for MS, but could AI or psychedelics provide a faster path to a cure?
With a new roadmap for MS research, are we on the verge of a drug that can repair the brain's wiring?
Precision Mapping of MS Models Unveils Path to Faster, More Effective Myelin Repair Therapies
Overview
A major new study published in 2026 used advanced single-cell RNA sequencing to directly compare the genetic activity in popular mouse models of multiple sclerosis (MS) with real human MS tissue. This breakthrough allows researchers to see how closely these animal models mimic the complex biology of human MS. By mapping these genetic similarities and differences, scientists can now choose the most accurate models for testing new myelin repair therapies. This new genetic roadmap is expected to speed up the development of effective treatments, making it more likely that future therapies will succeed in restoring myelin and improving outcomes for people with MS.